- Awakn Life Sciences ( OTCQB:AWKNF ) said CFO Kate Butler is leaving the company, effective July 31, to pursue other opportunities.
- The company said Jonathan Held, co-founder, chief business officer, and previous CFO has been appointed as interim CFO.
- In addition, Awakn said that it has launched 'Beta' phase of its licensing and partnerships business in North America. The company signed Memorandum of Understanding (MOU) with multiple clinics in North America.
- Once full agreements are signed, the clinics will get access to Awakn's ketamine-assisted therapy to treat alcohol use disorder, according to the company's July 15 press release.
- Awakn added that it has begun its Innovative Licensing and ccess Pathway (ILAP) application for its lead program Project Kestrel. ILAP is an initiative by the U.K. to support innovative approaches to develop medicines.
For further details see:
Awakn Life Sciences CFO resigns; inks contracts with clinics for alcohol use disorder therapy